Pfizer Inc, developed investigational elranatamab a cancer immunotherapy for the treatment of indivuduals with relapsed or refractory multiple myeloma (RRMM).
Elranatamab is bindedwith B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), present on the surface of multiple myeloma (MM) cells, and the CD3 receptor found on the surface of T-cells, bringingboth multiple myeloma (MM) cells and CD3 receptor together to activate the T-cells in order to kill myeloma cells.
BsAbs, a novel form of cancer immunotherapy directly targeting two different antigens at once. One arm binding directly to the specific antigens on cancer cells and the other arm binding to T-cells, allowing both the cells types together.
MM is a blood cancer devloped in the bone marrow affecting plasma cells. Healthy plasma cells build antibodies to fight body aginst infection.
In U.S, each year 34,000 new cases of MM are diagnosed. Multiple Myeloma remains uncurable inspite of having treatment advancements and the overall survival rate of patients with multiple myeloma is over five years, and most of the patients receive four or more lines of therapy.